Evidence item

Participants were treatment-naive, and gallbladder cancer comprised 72.5% of the analyzed population. MEASUREMENT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15122

Source: Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial · locator {} · excerpt hash sha256:3754890eae29dc3eee25fe12c5a3d2a03c61dd2232797f68558bcd6a9f5ea4c5

All included participants were treatment-naive for advanced or metastatic diseases. ... the predominant cancer subtype was GBC (72.5%).